ESR1 and breast carcinoma: Several clinical and experimental studies have indicated that tamoxifen, as an antiestrogen, seems to be effective in the palliative treatment of HCC, the same as breast cancer, via estrogen receptor (ER)-dependent or independent pathways [6,8,9].